Theravance Biopharma (NASDAQ: TBPH) reported Q1 EPS of ($0.35), $0.09 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $10.4 million versus the consensus estimate of $13.98 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.